دورية أكاديمية

Pulmonary vein dose and risk of atrial fibrillation in patients with non-small cell lung cancer following definitive radiotherapy: An NI-HEART analysis

التفاصيل البيبلوغرافية
العنوان: Pulmonary vein dose and risk of atrial fibrillation in patients with non-small cell lung cancer following definitive radiotherapy: An NI-HEART analysis
المؤلفون: Walls, Gerard M., McCann, Conor, O'Connor, John, O'Sullivan, Anna, Johnston, David I., McAleese, Jonathan, McGarry, Conor K., Cole, Aidan J., Jain, Suneil, Butterworth, Karl T., Hanna, Gerard G.
المصدر: Walls , G M , McCann , C , O'Connor , J , O'Sullivan , A , Johnston , D I , McAleese , J , McGarry , C K , Cole , A J , Jain , S , Butterworth , K T & Hanna , G G 2024 , ' Pulmonary vein dose and risk of atrial fibrillation in patients with non-small cell lung cancer following definitive radiotherapy: An NI-HEART analysis ' , Radiotherapy and Oncology , vol. 192 , 110085 . https://doi.org/10.1016/j.radonc.2024.110085Test
سنة النشر: 2024
المجموعة: Queen's University Belfast: Research Portal
مصطلحات موضوعية: /dk/atira/pure/subjectarea/asjc/2700/2720, name=Hematology, /dk/atira/pure/subjectarea/asjc/2700/2730, name=Oncology, /dk/atira/pure/subjectarea/asjc/2700/2741, name=Radiology Nuclear Medicine and imaging, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being
الوصف: Background and purpose Symptomatic arrhythmia is common following radiotherapy for non-small cell lung cancer (NSCLC), frequently resulting in morbidity and hospitalization. Modern treatment planning technology theoretically allows sparing of cardiac substructures. Atrial fibrillation (AF) comprises the majority of post-radiotherapy arrhythmias, but efforts to prevent this cardiotoxicity have been limited as the causative cardiac substructure is not known. In this study we investigated if incidental radiation dose to the pulmonary veins (PVs) is associated with AF. Material and methods A single-centre study of patients completing contemporary (chemo)radiation for NSCLC, with modern planning techniques. Oncology, cardiology and death records were examined, and AF events were verified by a cardiologist. Cardiac substructures were contoured on planning scans for retrospective dose analysis. Results In 420 eligible patients with NSCLC treated with intensity-modulated (70%) or 3D-conformal (30%) radiotherapy with a median OS of 21.8 months (IQR 10.8–35.1), there were 26 cases of new AF (6%). All cases were grade 3 except two cases of grade 4. Dose metrics for both the left (V55) and right (V10) PVs were associated with the incidence of new AF. Metrics remained statistically significant after accounting for the competing risk of death and cardiovascular covariables for both the left (HR 1.02, 95%CI 1.00–1.03, p = 0.005) and right (HR 1.01 (95%CI 1.00–1.02, p = 0.033) PVs. Conclusion Radiation dose to the PVs during treatment of NSCLC was associated with the onset of AF. Actively sparing the PVs during treatment planning could reduce the incidence of AF during follow-up, and screening for AF may be warranted for select cases.
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
العلاقة: https://pure.qub.ac.uk/en/publications/3aa3cfcf-0310-4715-9785-1a1d4044eecaTest
DOI: 10.1016/j.radonc.2024.110085
الإتاحة: https://doi.org/10.1016/j.radonc.2024.110085Test
https://pure.qub.ac.uk/en/publications/3aa3cfcf-0310-4715-9785-1a1d4044eecaTest
https://pureadmin.qub.ac.uk/ws/files/557100532/1-s2.0-S0167814024000069-main.pdfTest
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.7A859D5A
قاعدة البيانات: BASE